Stellar performance in the US generics segment and new product launches
According to consolidated financial results released Wednesday by Alembic Pharmaceuticals, net profit for the quarter ended September 30 climbed to 3.35 billion rupees ($35.37 million), up significantly from 1.85 billion rupees in the corresponding period of the previous fiscal year. Revenue from operations advanced over 36 percent to 26.03 billion rupees.
This robust expansion aligns closely with forecasts from analysts at Motilal Oswal, who anticipated that growth within Alembic's US generics division would be propelled by new product introductions encountering minimal competition.

















